Advanced Biomed Inc. - Common Stock (ADVB)

As metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH move toward large-scale clinical adoption, ENDRA Life Sciences (NASDAQ: NDRA) is emerging as a key player in solving one of the industry’s biggest challenges: scalable liver imaging .

Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”